Cancer Drug

The company's product is therapeutically equivalent to AstraZeneca UK's Calquence Capsules (100 mg)

Lupin on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America. The company in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, it said in a statement. The Mumbai-based drug maker's product is a generic version of Bristol-Myers Squibb Company's Sprycel tablets. As per IQVIA MAT data, Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US. Shares of Lupin settled at Rs 662.50 apiece, up 1.49 per cent on the BSE.

Drug firm Zydus Cadila on Wednesday said it has received tentative approval from the US health regulator to market Ibrutinib tablets used in the treatment of certain types of cancers.

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

US company Blueprint, which has been working with Roche since 2016, could also receive up to $927 million in milestone payments, plus royalties on sales outside the United States

The drug is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson

The study has found that the environment plays a statistically significant role in outcomes of cancers like acute leukaemia which need intensive treatment

It determined that people in poorer nations were on average 2.5 times more likely to die from heart disease than those in richer ones

The complex biological medicines, called antibody drug conjugates (ADCs), have been in development for decades

All companies have been asked to ensure that the price caps are adhered to.

This move is expected to benefit 22 lakh cancer patients in the country and would result in annual savings of around Rs 800 crore to the patients

However, it is not yet clear whether China has agreed to grant licences to Indian companies to sell cancer drug in the huge market

It is estimated that every year over 700,000 patients die due to various types of cancer in India

The single judge had also refused to revoke the patent of the Swiss company as sought by Cipla

Drugs worth over Rs 50 lakh were seized from a pharma dealer in Karol Bagh on May 4

The prices have been reduced in the range of 42% to 10%

According to the Food and Drugs Administration, drugs sold in the US are held to the same standards regardless of manufacturing location